Design and Synthesis of Novel 1-substituted-3-(3-(3-nitrophenyl)-4-oxo-3,4-dihydrobenzopyrimidin-2-yl amino) Isothioureas for their Anti-HIV, Antibacterial Activities, Graph Theoretical Analysis, Insilico Modeling, Prediction of Toxicity and Metabolic Studies

Abstract

In the present study, we have placed the substituted thiosemicarbazide moiety at the C-2 position and 3-nitrophenyl group at N-3 position of benzopyrimidines and studied their antitubercular, anti-HIV and antibacterial activities against selected gram positive and negative bacteria. The target compounds 1-substituted-3-(3-(3-nitrophenyl)-4-oxo-3,4-dihydrobenzopyrimidin-2-ylamino) isothioureas (PTS1 – PTS15 ) were obtained by the reaction of 2-hydrazino-3-(3-nitrophenyl) benzopyrimidin-4(3 H)-one (5) with different alkyl/aryl isothiocyanates followed by methylation with dimethyl sulphate. All synthesized compounds were screened for their antitubercular, anti-HIV and antibacterial activity against selective gram positive and gram negative bacteria by agar dilution method. Among the series, compound 2-methyl-3-(3-(3-nitrophenyl)-4-oxo-3,4-dihydrobenzopyrimidin-2-ylamino)-1-(3-chlorophenyl)isothiourea (PTS14) shown most potent activity against Klebsiella pneumoniae, Proteus vulgaris and Staphylococcus aureus; PTS14 exhibited the antitubercular activity at the minimum microgram of 1.56 µg/mL and anti-HIV activity at 0.96 µg/mL against HIV1 and HIV2 and offers potential for further optimization and development to new antitubercular and anti-HIV agents. The results obtained from this study confirm that the synthesized and biologically evaluated benzopyrimidines showed promising antimicrobial, antitubercular and anti-HIV activities and are new scaffolds for antimicrobial activity.

Key words

condensed pyrimidine - graph theoretical analysis - substituted thiosemicarbazide - antibacterial activity - antitubercular activity - anti-HIV activity

Publication History

Received: 30 June 2019

Accepted: 05 August 2019

Article published online:
19 June 2020

• References

• 1 World Health Organization, Global tuberculosis report 2018 World Health Organization: Geneva, Switzerland. 2018
• 2 Balcha TT, Skogmar S, Sturegård E. et al. Outcome of tuberculosis treatment in HIV-positive adults diagnosed through active versus passive case-finding. Glob Health Action 2015; 8: 27048
• 3 Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9: 173-184
• 4 World Health Organization Tuberculosis. Available online https://www.who.int/tb/en/ (accessed on 17 March 2019)
• 5 Alagarsamy V, Chitra K, Saravanan G. et al. An overview of quinazolines: Pharmacological significance and recent developments. Eur J Med Chem 2018; 151: 628-685
• 6 Hameed A, Al-Rashida M, Uroos M. et al. Quinazoline and quinazolinone as important medicinal scaffolds: A comparative patent review (2011-2016). Expert Opin Ther Pat 2018; 28: 281-297
• 7 Pavan FR, PIDaS Maia, Leite SR. et al. Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: Anti-Mycobacterium tuberculosis activity and cytotoxicity. Eur J Med Chem 2010; 45: 1898-1905
• 8 Güzel O, Karali N, Salman A. Synthesis and antituberculosis activity of 5-methyl/trifluoromethoxy-1H-indole-2,3-dione 3-thiosemicarbazone derivatives. Bioorg Med Chem 2008; 16: 8976-8987
• 9 Karali N, Gürsoy A, Kandemirli F. et al. Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives. Bioorg Med Chem 2007; 15: 5888-5904
• 10 Sriram D, Yogeeswari P, Thirumurugan R. et al. Discovery of new antitubercularoxazolylthiosemicarbazones. J Med Chem 2006; 49: 3448-3450
• 11 Sriram D, Yogeeswari P, Dhakla P. et al. 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. Bioorg Med Chem Lett 2009; 19: 152-1154
• 12 Saripinar E, Güzel Y, Patat S. et al. Electron-topological investigation of structure-antitubercular activity relationship of thiosemicarbazone derivatives. Arzneimittelforschung 1996; 46: 824-828
• 13 Milczarska B, Foks H, Sokołowska J. et al. Studies on pyrazine derivatives. XXXIII. Synthesis and tuberculostatic activity of 1-[1-(2-pyrazinyl)-ethyl]-4-N-substituted thiosemicarbazide derivatives. Acta Pol Pharm 1999; 56: 121-126
• 14 Turan-Zitouni G, Ozdemir A, Kaplancikli ZA. et al. Synthesis and antituberculosis activity of new thiazolylhydrazone derivatives. Eur J Med Chem 2008; 43: 981-985
• 15 Pandeya SN, Smitha S, Jyoti M. et al. Biological activities of isatin and its derivatives. Acta Pharmaceutica 2005; 55: 27-46
• 16 Meunier B. Hybrid molecules with a dual mode of action: Dream or reality?. Acc Che. Res 2008; 41: 69-77
• 17 Alagarsamy V, Solomon VR, Sheorey RV. et al. 3-(3-ethylphenyl)-2-substituted hydrazino-3H-quinazolin-4-one derivatives: New class of analgesic and anti-inflammatory agents. Chem Biol Drug Des 2009; 73: 471-479
• 18 Alagarsamy V, Appani R, Sulthana MT. et al. Design, synthesis and antimicrobial activities of 1-(4-oxo-3-(4-fluorophenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazide derivatives. J Chilean Chem Soc 2016; 61: 2856-2860
• 19 Sriram D, Yogeeswari P, Basha JS. et al. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 2005; 13: 5774-5778
• 20 Shanmugavelan P, Nagarajan S, Sathishkumar M. et al. Efficient synthesis and in vitro antitubercular activity of 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis. Bioorg Med Chem Lett 2011; 21: 7273-7276
• 21 Kunes J, Bazant J, Pour M. et al. Quinazoline derivatives with antitubercular activity. IL Farmaco 2000; 55: 725-729
• 22 Pauwels R, Clercq EDe, Desmyter J. et al. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. Virol Methods 1987; 16: 171-185
• 23 Barry A. Antibiotics in Laboratory Medicine,”. fifth ed William and Wilkins; Baltimore, MD: 1991: 1
• 24 Pandeya SN, Sriram D, Nath G. et al. Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine. IL Farmaco 1999; 54: 624-628
• 25 Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucl Acids Res 2000; 28: 27-30
• 26 Saravanan G, Panneerselvam T, Alagarsamy V. et al. Design, graph theoretical analysis, density functionality theories, Insilicomodeling, synthesis, characterization and biological activities of novel thiazole fused quinazolinone derivatives. Drug Dev Res 2018; 79: 260-274
• 27 Saravanan G, Panneerselvam T, Alagarsamy V. et al. Graph theoretical analysis, in silicomodeling, synthesis, anti-microbial and anti-TB evaluation of novel quinoxaline derivatives. Drug Rese 2018; 68: 250-262
• 28 Saravanan G, Panneerselvam T, Kunjiappan S. et al. Graph theoretical analysis, in silico modeling, prediction of toxicity, metabolism and synthesis of novel 2-(methyl/phenyl)-3-(4-(5-substituted-1,3,4-oxadiazol-2-yl) phenyl) quinazolin-4(3H)-ones as NMDA receptor inhibitor. Drug Dev Res DOI: 10.1002/ddr.21511.
• 29 İnkaya E, Dinçer M, Ekici O. et al. N′-(2-methoxy-benzylidene)-N-[4-(3-methyl-3-phenyl-cyclobutyl)-thiazol-2-yl]-chloro-acetic hydrazide: X-ray structure, spectroscopic characterization and DFT studies. J Mol Str 2012; 1026: 117-126
• 30 Güntepe F, Saraçoğlu H, Çalışkan N. et al. Synthesis, molecular and crystal structure analysis of 2-bromo-4-chloro-6-{[4-(3-methyl-3-phenyl-cyclobutyl)-thiazol-2-yl]-hydrazonomethyl}-phenol by experimental methods and theoretical calculations. J Mol Str 2012; 1022: 204-210
• 31 Rydberg P, Gloriam DE, Olsen L. The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics 2010; 26: 2988-2989